Brainstorm Cell Therapeutics, Inc. (OTC BB: BCLI), a leading developer of stem cell technologies, is committed to providing treatments for neurodegenerative diseases that are currently incurable. The company’s focus is on developing NTF cells from the patient’s own bone marrow to treat, Parkinson, ALS, and Spinal Cord Injury. The Brainstorm management and scientific teams are devoted to the company’s mission to regenerate the mind in their lifetime. For further information, visit the Company’s web site at www.brainstorm-cell.com.
- 18 years ago
QualityStocks
Brainstorm Cell Therapeutics, Inc. (OTC BB: BCLI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Hallmark Venture Group, Inc. (OTC: HLLK) Completes Drone Technology Acquisition, Transitions to Operating Business
Hallmark Venture Group (OTC: HLLK) announced the completion of a strategic transaction that transforms the company from…
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on DNA Repair Cancer Therapies
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced…
-
QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Releases RoadSight UGV Demonstration Video
Safe Pro Group (NASDAQ: SPAI), has released a demonstration video highlighting its new RoadSight capability,…